Merck Animal Health Provides $100,000 Sponsorship to the University of Georgia College of Veterinary Medicine

Sponsorship to Support Veterinary Student in College’s Poultry Diagnostic and Research Center

MADISON, N.J., January 29, 2015 – Merck Animal Health (known as MSD Animal Health outside the USA and Canada) today announced a sponsorship of $100,000 to the University of Georgia College of Veterinary Medicine, Athens, Ga. The sponsorship will provide educational support to a student attending the College’s Poultry Diagnostic and Research Center (PDRC) over a three-year period. 

The sponsorship award recipient, Grace Ashby, is a doctoral candidate whose passion for advancing poultry health, production and management led to her 2014 acceptance to PDRC. Ashby earned a B.S.A. in avian biology from the University of Georgia, has served as a poultry surgery teaching assistant and completed internships at the Georgia Poultry Laboratory Network in Oakwood, Ga., and Pilgrim’s Pride Corporation in Athens, Ga. Ashby looks forward to continuing her education through research and contributing to the development of new vaccine methods and respiratory health. 

“Merck Animal Health is proud to invest in the future of the veterinary profession,” said Dr. Charlie Broussard, Associate Director, Scientific Marketing Affairs, Merck Animal Health. “We are committed to the science of healthier animals and believe this sponsorship will help prepare students for their careers and contribute to advancements in poultry health and performance.” 

In addition to training students, the Poultry Diagnostic and Research Center also conducts research on the diagnosis and control of poultry diseases and provides field services to the poultry industry. The Center’s three-fold mission of teaching, research and service, helps prepare students for careers in research and medicine, while also addressing problems of importance to the poultry industry. 

“We are pleased to receive this scholarship from Merck Animal Health,” said Dr. Mark W. Jackwood, the J.R. Glisson Professor of Veterinary Medicine and Head of the Department of Population Health at the University of Georgia College of Veterinary Medicine. “These funds will help us continue providing our students with the education and experience they need for a successful career in avian medicine, as well as offering valuable research and services to the poultry industry.” 

Every year, Merck Animal Health collaborates with numerous educational and veterinary organizations to ensure the advancement of animal health. This sponsorship program is part of a broader commitment to education, students and the future of the industry.  

To learn more about the Poultry Diagnostic and Research Center at the University of Georgia, visit

About Merck Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit  or connect with us on LinkedIn and Twitter at @MerckAH.

Merck Forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2013 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site ( ).